Functional, sustained recovery of hearing in Otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy
Molecular Therapy Methods & Clinical Development · 2025-12 · 33 (4) · 101577
DOI: 10.1016/j.omtm.2025.101577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Methods & Clinical Development, 2025-12. Verfasst von Yoojin Chung und 27 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regeneron Pharmaceuticals.
Abstract (Originalsprache)
Biallelic loss-of-function variants in the Otoferlin gene (OTOF) lead to congenital hearing loss in both humans and mice. We developed DB-OTO, a hair-cell-specific adeno-associated virus (AAV)-based dual-vector gene therapy designed to restore hearing in individuals with OTOF-related hearing loss. DB-OTO is composed of two AAV1 vectors that reconstitute a functional OTOF gene expression cassette to form the full-length human OTOF variant 5 (h OTOFv5). A synthetic promoter (mMyo15) based on the murine Myosin 15 a gene was engineered to restrict the transgene expression to hair cells. The promoter construct was chosen after comparison of multiple variants using a GFP reporter in ex vivo murine explant models, followed by in vivo studies in wild-type mice and cynomolgus macaques. Comparison between the 1.0 kb mMyo15 and a ubiquitous promoter driving expression of h OTOFv5 transgene in mice showed that hair-cell-specific expression is critical for safe expression of otoferlin. DB-OTO induced dose-dependent establishment of auditory brainstem response, and OTOF expression in inner hair cells over a 10-fold dose range sustained for at least 3 months in a mouse model of OTOF deficiency. These data supported the initiation of an ongoing phase I/II clinical trial of DB-OTO in pediatric patients with OTOF-related hearing loss.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591, USA.
- Decibel Therapeutics, Inc., Boston, MA 02215, USA.
- Brigham and Women's Hospital, Boston, MA 02115, USA.
- Boston Medical Center, Boston, MA 02118, USA.
Förderung
- Regeneron Pharmaceuticals
Zitieren
APA
Chung, Y., Koehler, S. D., Cancelarich, S., Gibson, T. M., Pregernig, G., Becker, L., Artinian, Q. A., Goodliffe, J. W., Pan, N., Quigley, T. M., Senapati, A., Slade, P. G., Smith, L. M., So, K. S., Zhang, X., Corrales, C. E., Weber, P., Macdonald, L. E., Zambrowicz, B., …, & Drummond, M. C. (2025). Functional, sustained recovery of hearing in Otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy. Molecular Therapy Methods & Clinical Development, 33(4), 101577. https://doi.org/10.1016/j.omtm.2025.101577
Vancouver
Chung Y, Koehler SD, Cancelarich S, Gibson TM, Pregernig G, Becker L, et al. Functional, sustained recovery of hearing in Otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy. Molecular Therapy Methods & Clinical Development. 2025;33(4):101577. doi:10.1016/j.omtm.2025.101577
BibTeX
@article{Chung2025,
author = {Chung, Yoojin and Koehler, Seth D and Cancelarich, Sarah and Gibson, Tyler M and Pregernig, Gabriela and Becker, Lars and Artinian, Quynh-Anh and Goodliffe, Joseph W and Pan, Ning and Quigley, Tera M and Senapati, Arun and Slade, Peter G and Smith, Lillian M and So, Kathy S and Zhang, Xichun and Corrales, C Eduardo and Weber, Peter and Macdonald, Lynn E and Zambrowicz, Brian and Economides, Aris N and Kyratsous, Christos A and Burns, Joseph C and Palermo, Adam T and Sabin, Leah R and Lee, John and Valayannopoulos, Vassili and Whitton, Jonathon P and Drummond, Meghan C},
title = {Functional, sustained recovery of hearing in Otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy},
journal = {Molecular Therapy Methods & Clinical Development},
year = {2025},
volume = {33},
number = {4},
pages = {101577},
doi = {10.1016/j.omtm.2025.101577}
}
EUVIMED